Exchange: NASDAQ·Updated 07:52 PM EDT

ALEC News

News
all
press releases
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Stocktwits
More News
Biotech Junior Gains 21% as US$100M Upfront Pharma Deal Extends Cash Runway
Securing upfront cash equal to roughly half of its market value sent a small neuroscience developer sharply higher Monday, a reminder of how much a big pharma license can say about a preclinical delivery platform. Alector Inc. (NASDAQ: ALEC) rallied after signing an exclusive global license agreement with Genentech, a member of the Roche Group, for AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. Alector will receive US$100M upfront and is eligible for up to US$1.17B in development, regulatory and commercial milestone payments, plus tiered ...
AllPennyStocks.com
Brainiacs, Space Men, and Digital Assets
This week’s action puts Alector (NASDAQ:ALEC), NeOnc Technologies (NASDAQ:NTHI), WISeQey (NASDAQ:WKEY), Veea (NASDAQ:VEEA), and Stablecoin Development Corporation (NYSEAMERICAN:SDEV) squarely in that conversation.
24-7 Market News
Alector Lands $1.27 Billion Genentech Deal, as Brain-Delivery Platform Gets a Major Validation
Alector (NASDAQ:ALEC) just transformed one of its most important neuroscience programs into a potentially billion-dollar commercial opportunity.
24-7 Market News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares increasedread more...
Benzinga
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.read more...
Benzinga
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.